Therapeutically, blocking HVEM–LIGHT co-stimulation might benefit IBD. Conversely, agonists of HVEM’s inhibitory ligand BTLA could mimic HVEM deficiency’s anti-inflammatory effect. Here, TNFSF14 is linked to inflammatory bowel disease.